Opioid use disorder is an addiction crisis in the United States that has become increasingly lethal during the COVID-19 pandemic. To preserve access to life-saving treatment during the pandemic, federal drug agencies loosened requirements on physicians for treating these patients, including moving patient evaluations away from in-person exams to telemedicine. This federal policy change focused primarily on buprenorphine, a highly effective treatment for opioid use disorder and one that is much less onerous and stigmatizing than methadone, the other most…
